On Friday, Merck & Co. and Ridgeback Biotherapeutics announced that an experimental pill they developed together promised to cut the risk of hospitalization or death from COVID-19 by roughly 50 percent. The drug, called molnupiravir, is in late-stage trials and could be authorized for emergency use by the end of the year.
Merck’s New COVID Pill Could Be a Game-Changer. Where Have We Heard That Before?
